|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Substance Use Disorders | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Attention Deficit Disorder with Hyperactivity | |||||
| Disease | |||||
| Hyperkinesis | |||||
| Substance-Related Disorders | |||||
| 3 | More general conditions related to this trial | ||||
| Attention Deficit and Disruptive Behavior Disorders | |||||
| Disorders of Environmental Origin | |||||
| Dyskinesias | |||||
| Mental Disorders | |||||
| Mental Disorders Diagnosed in Childhood | |||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Pathologic Processes | |||||
| Signs and Symptoms | |||||
| 4 | Interventions listed in this trial | ||||
| Atomoxetine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adrenergic Agents | |||||
| Adrenergic Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | |||||